BrainsWay Ltd (BRSYF) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of BrainsWay Ltd $15.34, price $12.60, upside +21.8%, quality 60 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch BrainsWay Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range $0.0200 – $16.84 · fair‑value band $10.74 – $19.96 · the $12.60 price screens below the $15.34 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow BrainsWay in your weekly email
Every Wednesday you see whether BrainsWay is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally.
Show more
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious and late-life depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.
Stock analysis
BrainsWay Ltd (BRSYF) currently trades at $12.60, while our model-based Fair Value estimate is $15.34, implying the stock looks roughly 17.9% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of $8.65 per share, and 0 of the 24 models we run sit above the $12.60 price.
Bear case: the Economic Profit group reads lowest at $1.73, and 24 of the 24 models stay below the price. Evidence for this calculation is medium.
Scenario range: $10.74 (bear) to $19.96 (bull), the price of $12.60 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 60/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
BrainsWay Ltd reported revenue of $56.5M in FY2025 versus $29.7M in FY2021, a compound +17.5%/yr. Reported net income was $8.3M in FY2025.
Key figures
Market cap $676M · P/E ratio 57.3 · P/S ratio 8.37 · EPS (TTM) $0.2200 · Net margin 14.6% · Return on equity 12.6% · Return on assets (EBIT) −5.7% · Operating margin 12.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 54 out of 100 (low confidence).
What moves the price
The share trades about 25% below its 52-week high and 130% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at 22%, BRSYF screens cheaper than that median.
Fair Value models
Bear $10.74Fair Value $15.34Bull $19.96
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($0.1664 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.100/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+37.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+27.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+20.7%
Start year 2020 (pandemic). Over 10 years: +23.6% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+47.4%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−21.9% (2020) → 8.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+15.0%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+19.0%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +12.3% a year for the price and +16.3% for the forecasts.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 351 stocks
Beats the industry median on 7/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score60 · Above median
Fair Value upside+7.8% · Above median
Profitability
Return on equity (TTM)12.6% · Top 25%
Return on assets3.3% · Above median
Net margin (TTM)15.6% · Top 25%
Operating margin (TTM)12.9% · Above median
Growth and dividend
Revenue growth34.6% · Top 25%
Valuation Multiplesvs Medical Devices median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "BrainsWay Ltd Fair Value". https://www.fairvalue-calculator.com/stock/BRSYF
Frequently asked questions
Is BrainsWay Ltd (BRSYF) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $15.34 versus a price of $12.60, about +22% upside (undervalued).
What is the fair value of BRSYF?
Our model-based fair value for BrainsWay Ltd is $15.34 (as of Sep 24, 2026), built from audited fundamentals. The current price: $12.60.
What is the quality score of BRSYF?
BrainsWay Ltd has a Quality Score of 60/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for BrainsWay Ltd (BRSYF)?
Our model-based price target is the fair value of $15.34 (as of Sep 24, 2026) from 24 valuation models. Cautious scenario $10.74, optimistic scenario $19.96. It is a calculation from audited fundamentals, not an analyst target.
What is the BrainsWay Ltd stock forecast for 2026?
Our models put fair value at $15.34, about +22% upside versus a price of $12.60 (undervalued). Cautious scenario $10.74, optimistic scenario $19.96. The calculation is refreshed regularly with new filings.
What is the revenue of BrainsWay Ltd (BRSYF)?
BrainsWay Ltd reported trailing-twelve-month revenue of about $56.2M (latest available figure, as of Sep 24, 2026).
What growth is priced into BrainsWay Ltd (BRSYF)?
For today's price to be fair in a discounted-cash-flow model, BrainsWay Ltd would have to grow free cash flow by +15.0 % per year for five years (discount rate 9.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +20.7 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of BRSYF use?
Our models discount BrainsWay Ltd at 9.8 %: a base by market capitalisation (small), damped by beta 0.15, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For BrainsWay Ltd that is +15.0 % per year a year over ten years, using the same discount rate (9.8 %) and the same formula as our fair value.
How much growth has BrainsWay Ltd (BRSYF) delivered so far?
Over the past 5 years revenue at BrainsWay Ltd grew +20.7 % a year. The price currently implies +15.0 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of BrainsWay Ltd (BRSYF) growing?
The median revenue growth in the sector is +5.1 % a year. That is the yardstick for the growth priced into BrainsWay Ltd (+15.0 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of BrainsWay Ltd (BRSYF)?
The free-cash-flow yield on the price is 3.30 %: that much free cash flow BrainsWay Ltd produces per unit of market value. When it exceeds the discount rate of our models (9.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of BrainsWay Ltd (BRSYF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For BrainsWay Ltd it is $15.34 per share (as of Sep 24, 2026), against a price of $12.60. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is BrainsWay Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, BRSYF trades below its calculated fair value: price $12.60, fair value $15.34, a gap of about +22% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BRSYF?
No. The price is what the market pays today ($12.60); the fair value is what the company's own numbers justify ($15.34). For BrainsWay Ltd the two are $2.74 per share apart. That gap is exactly why we show both numbers side by side.
How much is BrainsWay Ltd worth?
The market values BrainsWay Ltd at about $676M (market capitalisation, as of Sep 24, 2026). Per share that is $12.60; our models calculate a fair value of $15.34 per share.
What do the bullish and bearish scenarios say about BRSYF?
Our models span a range for BrainsWay Ltd: cautious scenario $10.74, base $15.34, optimistic $19.96 per share (as of Sep 24, 2026, price $12.60). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of BRSYF?
BrainsWay Ltd trades at a price-to-earnings ratio of 57.3 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $15.34 is built from several models across several years. Other multiples: P/B 8.8, P/S 11.4, EV/EBITDA 86.7.
How solid is the balance sheet of BrainsWay Ltd (BRSYF)?
Balance-sheet figures for BrainsWay Ltd (as of Sep 24, 2026): return on equity 12.6%. They feed the Quality Score of 60/100, which measures business quality independently of the share price.
How far is BRSYF from its 52-week high?
BrainsWay Ltd trades at $12.60, about 25% below its 52-week high of $16.84 and 130% above the low of $5.49 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $15.34 is for.
Which stocks are comparable to BrainsWay Ltd?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is BrainsWay Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price $12.60, calculated fair value $15.34 (+22%), Quality Score 60/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BRSYF calculated?
We run BrainsWay Ltd through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $15.34, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. BrainsWay Ltd currently trades 18 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of BrainsWay Ltd (BRSYF)?
The closing price on Oct 2, 2026 was $12.60. Our model-based fair value is $15.34, about +22% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with BrainsWay Ltd right now?
Solid quality (60/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range ($10.74 to $19.96) leaves room in how you read the outcome.
Key figures of BrainsWay Ltd
How large is the market capitalisation of BrainsWay Ltd (BRSYF)?
The market capitalisation of BrainsWay Ltd is $676M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of BrainsWay Ltd (BRSYF)?
The price-to-sales ratio of BrainsWay Ltd is 8.37 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of BrainsWay Ltd (BRSYF)?
Earnings per share at BrainsWay Ltd are $0.2200 (price ÷ EPS = P/E 57.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of BrainsWay Ltd (BRSYF)?
The net margin of BrainsWay Ltd is 14.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of BrainsWay Ltd (BRSYF)?
The return on equity (ROE) of BrainsWay Ltd is 12.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of BrainsWay Ltd (BRSYF)?
On an EBIT basis the return on assets of BrainsWay Ltd is −5.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of BrainsWay Ltd (BRSYF)?
The operating margin of BrainsWay Ltd is 12.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at BrainsWay Ltd (BRSYF)?
Revenue at BrainsWay Ltd is growing +34.6% versus a year earlier (3y avg +27.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at BrainsWay Ltd (BRSYF)?
Earnings per share at BrainsWay Ltd are growing +200% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does BrainsWay Ltd (BRSYF) hold?
BrainsWay Ltd holds more cash than debt, $61.1M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch BrainsWay Ltd in the live analysis
One click puts BrainsWay Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Some data
Sep 24, 2026